Autoimmune thyroiditis Part 2 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

This is Part 2 of Dr. Holtorf’s 3-part series on autoimmune thyroiditis as a core cause of hypothalamic pituitary dysfunction, mitochondrial dysfunction, obesity and systemic illness

Autoimmune thyroiditis Part 1 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

Lyme Disease - Darin Ingels, ND (2021 Conference) (LDN, low dose naltrexone)

SIBO - Leonard Weinstock, MD (2021 Conference) (LDN, low dose naltrexone)

Opiate Receptor Drugs – To Cycle or Not to Cycle Dosing? - Paul Anderson, NMD (2021 Conference) (LDN, low dose naltrexone)

History, Pharmacology and Mechanism - Stephen Dickson, BSC (hons) MRPharmS (2021 Conference) (LDN, low dose naltrexone)

LDN Research Trust 2021 Conference - Friday Morning

Stephen Dickson, BSC (hons) MRPharmS - Mechanism of Action of Low Dose Naltrexone (2019 Conference) (LDN, low dose naltrexone)

LDN 2019 Conference - Saturday Afternoon Q&A (2019 Conference) (LDN, low dose naltrexone)

Presentations on the below and questions were asked in relation to:

LDN 2019 Conference - Saturday Morning Q&A (2019 Conference) (LDN, low dose naltrexone)

Presentations on the below and questions were asked in relation to:

Samyadev Datta, MD - Pharmacology of Low dose Naltrexone in Chronic Pain Management (2019 Conference) (LDN, low dose naltrexone)

Samyadev Datta, MD discusses LDN and ultra-low dose naltrexone (ULDN) to treat chronic pain and inflammatory/autoimmune conditions. He presents on the history and pharmacology of naltrexone, forms in which LDN can be prepared. Several case studies on pain are presented